SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.

Abstract

BACKGROUND In patients with type 2 diabetes, improving adherence to medication is important in order to maintain favourable glycaemic control during long-term treatment and, thus, prevent the onset or aggravation of complications. SYR-472 is a novel once-weekly oral DPP-4 inhibitor for type 2 diabetes, which could be a treatment option when clinicians seek… (More)
DOI: 10.1016/S2213-8587(13)70149-9

Topics

8 Figures and Tables

Cite this paper

@article{Inagaki2014SYR472AN, title={SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.}, author={Nobuya Inagaki and Hitoshi Onouchi and Hiroki Sano and Nobuo Funao and Shingo Kuroda and Kohei Kaku}, journal={The lancet. Diabetes & endocrinology}, year={2014}, volume={2 2}, pages={125-32} }